Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

被引：0
|
作者：
R. Mercieca-Bebber
E. H. Barnes
K. Wilson
Z. Samoon
E. Walpole
T. Mai
S. Ackland
M. Burge
G. Dickie
D. Watson
J. Leung
T. Wang
R. Bohmer
D. Cameron
J. Simes
V. Gebski
M. Smithers
J. Thomas
J. Zalcberg
A. P. Barbour
机构：
[1] University of Sydney,National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Faculty of Medicine and Health
[2] Princess Alexandra Hospital,Division of Cancer Services
[3] University of Queensland,School of Clinical Medicine
[4] The University of Queensland,Faculty of Medicine
[5] University of Newcastle,School of Medicine and Public Health
[6] Royal Brisbane and Women’s Hospital,Cancer Care Services
[7] Flinders University,Discipline of Surgery, College of Medicine and Public Health
[8] GenesisCare St Andrew’s Hospital,Crown Princess Mary Cancer Center, Westmead hospital; Faculty of Medicine and Health
[9] University of Sydney,School of Public Health and Preventive Medicine
[10] Hobart Private Hospital,undefined
[11] Townsville University Hospital,undefined
[12] Divisions of Surgery and Cancer Services,undefined
[13] Princess Alexandra Hospital,undefined
[14] GIAST Clinic Mater Medical Centre South Brisbane,undefined
[15] Monash University,undefined
来源：
BMC Cancer | / 22卷
关键词：
Oesophageal adenocarcinoma; Gastro-oesophageal adenocarcinoma; Neoadjuvant therapy; Quality of life; Patient-reported outcomes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
    Mercieca-Bebber, R.
    Barnes, E. H.
    Wilson, K.
    Samoon, Z.
    Walpole, E.
    Mai, T.
    Ackland, S.
    Burge, M.
    Dickie, G.
    Watson, D.
    Leung, J.
    Wang, T.
    Bohmer, R.
    Cameron, D.
    Simes, J.
    Gebski, V
    Smithers, M.
    Thomas, J.
    Zalcberg, J.
    Barbour, A. P.
    BMC CANCER, 2022, 22 (01)
  • [2] Patient-reported outcome (PRO) results from AGITG DOCTOR: A randomised phase II trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
    Mercieca-Bebber, R.
    Barnes, E. H.
    Wilson, K.
    Samoon, Z.
    Walpole, E. T.
    Mai, T.
    Ackland, S.
    Burge, M.
    Dickie, G.
    Watson, D.
    Leung, J.
    Wang, T.
    Bohmer, R.
    Cameron, D.
    Simes, R.
    Gebski, V.
    Smithers, M.
    Thomas, J.
    Zalcberg, J. R.
    Barbour, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S903 - S904
  • [3] The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank
    Lonie, James M.
    Brosda, Sandra
    Bonazzi, Vanessa F.
    Aoude, Lauren G.
    Patel, Kalpana
    Brown, Ian
    Sharma, Sowmya
    Lampe, Guy
    Addala, Venkateswar
    Koufariotis, Lambros T.
    Wood, Scott
    Waddell, Nicola
    Dolcetti, Riccardo
    Barbour, Andrew P.
    FRONTIERS IN IMMUNOLOGY, 2023, 14 : 1220129
  • [4] Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial
    Barbour, A. P.
    Walpole, E. T.
    Mai, G. T.
    Barnes, E. H.
    Watson, D., I
    Ackland, S. P.
    Martin, J. M.
    Burge, M.
    Finch, R.
    Karapetis, C. S.
    Shannon, J.
    Nott, L. M.
    Varma, S.
    Marx, G.
    Falk, G. L.
    Gebski, V
    Oostendorp, M.
    Wilson, K.
    Thomas, J.
    Lampe, G.
    Zalcberg, J. R.
    Simes, J.
    Smithers, B. M.
    ANNALS OF ONCOLOGY, 2020, 31 (02) : 236 - 245
  • [5] Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)
    Snyder, Rebecca A.
    Dueck, Amylou C.
    Fruth, Briant
    Shi, Qian
    Hubbard, Joleen M.
    Herman, Joseph M.
    O'Reilly, Eileen M.
    Katz, Matthew H. G.
    ANNALS OF SURGERY, 2023, 278 (04) : 598 - 608
  • [6] Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072)
    Alderson, Derek
    Langley, Ruth E.
    Nankivell, Matthew Guy
    Blazeby, Jane M.
    Griffin, Michael
    Crellin, Adrian
    Grabsch, Heike I.
    Okines, Alicia Frances Clare
    Goldstein, Cindy
    Falk, Stephen
    Thompson, Joyce
    Krysztopik, Richard
    Coxon, Fareeda Y.
    Pritchard, Susan
    Langer, Rupert
    Stenning, Sally Patricia
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (PRO-HF) Trial
    Sandhu, Alexander T.
    Zheng, Jimmy
    Kalwani, Neil M.
    Gupta, Anshal
    Calma, Jamie
    Amano, Alexis
    Johnson, Cati
    Winget, Marcy
    Heidenreich, Paul A.
    CIRCULATION, 2022, 146 (25) : E572 - E572
  • [8] PERFORMANCE OF THE SCLERODERMA SKIN PATIENT-REPORTED OUTCOME (SSPRO) IN A PHASE 2 TRIAL WITH LENABASUM
    Man, Ada
    Dgetluck, Nancy
    Conley, Brian
    White, Barbara
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 848 - 849
  • [9] Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial
    Krueger, GG
    Langley, RG
    Finlay, AY
    Griffiths, CEM
    Woolley, JM
    Lalla, D
    Jahreis, A
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (06) : 1192 - 1199
  • [10] Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
    Siena, S.
    Peeters, M.
    Van Cutsem, E.
    Humblet, Y.
    Conte, P.
    Bajetta, E.
    Comandini, D.
    Bodoky, G.
    Van Hazel, G.
    Salek, T.
    Wolf, M.
    Devercelli, G.
    Woolley, M.
    Amado, R. G.
    BRITISH JOURNAL OF CANCER, 2007, 97 (11) : 1469 - 1474
12345